文献类型：期刊文献

英文题名：Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis

作者：Wang, Yongfeng[1,2,3,4];Fu, Liangyin[1,2,3];Lu, Tingting[5];Zhang, Guangming[1,2,3];Zhang, Jiawei[6];Zhao, Yuanbin[6];Jin, Haojie[7];Yang, Kehu[4,5,8];Cai, Hui[1,2,3]

第一作者：Wang, Yongfeng;汪永锋

通信作者：Cai, H[1];Cai, H[2];Cai, H[3]

机构：[1]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou, Peoples R China;[3]Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, Lanzhou, Peoples R China;[4]Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Peoples R China;[5]Gansu Prov Hosp, Inst Clin Res & Evidence Based Med, Lanzhou, Peoples R China;[6]Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China;[7]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China;[8]Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou, Peoples R China;[3]corresponding author), Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;

年份：2021

卷号：12

外文期刊名：FRONTIERS IN GENETICS

收录：;Scopus(收录号：2-s2.0-85117179485);WOS:【SCI-EXPANDED(收录号:WOS:000710474300001)】；

基金：This study was supported by the Natural Science Foundation of Gansu Province, China (No. 18JR3RA052); National Scientific Research Project Cultivation Plan of Gansu Provincial People's Hospital (No. 2019-206); Lanzhou Talent Innovation and Entrepreneurship Project Task Contract (No. 2016-RC-56); National Key Research and Development Program (No. 2018YFC1311500); Fundamental Research Funds for the Central Universities (No. 2020jbkyzx001; lzujbky-2020-kb20); and 2021 Graduate Innovation Fund Project of Gansu University of Traditional Chinese Medicine, No. 2021CX54.

语种：英文

外文关键词：lncRNA; MIAT; cancer; prognosis; meta-analysis

摘要：Background: Although the treatment of cancer has made evident progress, its morbidity and mortality are still high. A tumor marker is a critical indicator for early cancer diagnosis, and timely cancer detection can efficiently help improve the prognosis of patients. Therefore, it is necessary to identify novel markers associated with cancer. LncRNA myocardial infarction associated transcript (MIAT) is a newly identified tumor marker, and in this study, we aimed to explore the relationship between MIAT and clinicopathological features and patient prognosis.

Methods: We searched PubMed, Embase, Web of Science, and The Cochrane Library from inception to September 2020 to identify correlational studies. Then, we extracted valid data and used Stata software to make forest plots. We used the hazard ratio (HR) or odds ratio (OR) with 95% CI to evaluate the relationship between aberrant expression of MIAT and patients' prognosis and clinicopathological features.

Results: The study included 21 studies, containing 2,048 patients. Meta-analysis showed that overexpression of lncRNA MIAT was associated with poor overall survival (OS) (HR = 1.60, 95% CI, 1.31-1.96, p < 0.001). In addition, high expression of MIAT could forecast tumor size (OR = 2.26, 95% CI 1.34-3.81, p = 0.002), distant metastasis (OR = 2.54, 95% CI 1.84-3.50, p < 0.001), TNM stage (OR = 2.38, 95% CI 1.36-4.18, p = 0.002), lymph node metastasis (OR = 2.59, 95% CI 1.25-5.36, p = 0.011), and the degree of differentiation (OR = 2.65, 95% CI 1.54-4.58, p < 0.001). However, other clinicopathological features, including age (OR = 1.07, 95% CI 0.87-1.32, p = 0.516), gender (OR = 0.95, 95% CI 0.77-1.19, p = 0.668), and histology (OR = 0.72, 95% CI 0.48-1.10, p = 0.128) were not significantly different from high expression of MIAT.

Conclusions: Our study showed that overexpression of MIAT is related to poor overall survival and clinicopathological features. MIAT can be considered a novel tumor marker to help diagnose tumors earlier and improve patient prognosis.